Illumina, Inc. Reports Earnings Results for the Fourth Quarter Ended December 29, 2019
January 29, 2020 at 09:10 pm
Share
Illumina, Inc. announced earnings results for the fourth quarter ended December 29, 2019. For the fourth quarter, the company announced total revenue was USD 953 million compared to USD 867 million a year ago. Operating income was USD 268 million compared to USD 197 million a year ago. Net income was USD 239 million compared to USD 210 million a year ago. Basic earnings per share was USD 1.63 compared to USD 1.43 a year ago. Diluted earnings per share was USD 1.61 compared to USD 1.41 a year ago. For the full year, total revenue was USD 3,543 million compared to USD 3,333 million a year ago. Operating income was USD 985 million compared to USD 883 million a year ago. Net income was USD 1,002 million compared to USD 826 million a year ago. Basic earnings per share was USD 6.81 compared to USD 5.63 a year ago. Diluted earnings per share was USD 6.74 compared to USD 5.56 a year ago.
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
ILLUMINA, INC. 
